Thursday, June 12, 2025
LBNN
  • Business
  • Markets
  • Politics
  • Crypto
  • Finance
  • Energy
  • Technology
  • Taxes
  • Creator Economy
  • Wealth Management
  • Documentaries
No Result
View All Result
LBNN

Researchers engineer nanostructures to enhance the immune system’s ability to combat cancer

Simon Osuji by Simon Osuji
July 14, 2023
in Technology
0
Researchers engineer nanostructures to enhance the immune system’s ability to combat cancer
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Researchers engineer nanostructures to enhance the immune system's ability to combat cancer
Synthesis of CDN-conjugated NPs. Cationic pBAEs are formulated by mixing acrylate-terminate pBAE polymer with arginine-oligopeptide (termed C6-CR3). Maleimide-modified ML-317 is conjugated to pBAE by the Diels–Alder reaction (termed ML-317-Linker-pBAE). After CDN conjugation, ML-317-Linker-pBAE polymer is electrostatically complexed with C6-CR3 polymer, resulting in the formation of covalently conjugated CDN-NP. CDN-NPs are PEGylated using NHS-PEG and purified and sterilized by filtration. CDN is released from the CDN-NPs through a cathepsin-cleavable linker in the cell cytoplasm. Credit: Nature Nanotechnology (2023). DOI: 10.1038/s41565-023-01447-7

Over the past decade, researchers have sought more effective and enduring cancer treatments. Among the wide variety of immunotherapies, Stimulator of Interfron Genes activation (STING agonism) has emerged as a particularly promising approach that harnesses a patient’s immune system to combat tumors throughout the body.

Related posts

Save oceans from dangers of plastic waste, France urges global community – EnviroNews

Save oceans from dangers of plastic waste, France urges global community – EnviroNews

June 12, 2025
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

June 12, 2025

Although potentially revolutionary, there remain critical hurdles to overcome before STING agonism can be employed as treatment option for patients. For example, the intravenous administration of STING agonist drugs is often not effective, due to lack of drug stability and poor uptake by immune cells.

Addressing these challenges head-on, investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, have now designed stimuli-responsive nanoparticle structures, allowing STING agonist drugs to be released when reaching the target cells. In a paper published today in Nature Nanotechnology, the researchers report that stabilized nanoformulations not only eradicated active tumors in mice but also trained their immune systems to recognize and eliminate future tumors.

“Our goal is to use STING agonism to instruct the immune system to treat cancer cells as invaders, which necessitates the design of stable and potent nanostructures that enable STING to reach the right organs and the right cells,” said senior author Natalie Artzi, Ph.D., a principal investigator in the Brigham’s Department of Medicine.

Lead author Pere Dosta Pons, Ph.D., an instructor in the Brigham’s Department of Medicine, highlighted the novelty of their approach: “We not only are training the immune system to target and eliminate cancer cells, but also to generate immune memory for preventing cancer recurrence.”

STING agonism involves the activation of a protein called the stimulator of interferon genes (STING), which alerts the immune system to the presence of invaders. When the body is infected by a virus or bacterial species, small messenger molecules known as cytosolic cyclic dinucleotides (CDN) attach themselves to STING. This activation prompts the production of proinflammatory cytokines, which in turn activate immune cells such as natural killer cells, macrophages, and T-cells, recruiting them to the affected area to clear the infection.

Cancer evades this STING pathway by disguising itself as the body’s own cells. Researchers have been attempting to teach the immune system to identify and attack cancer cells by delivering STING agonists to immune cells in the tumor microenvironments and tumor-draining lymph nodes.

In their new paper, the Brigham team describes a new nanoparticle structure that more effectively transports CDN molecules into immune cells. This structure directly connects laboratory-produced CDNs to nanoparticles made of poly(beta amino esters), or pBAEs, making the compound more stable and potent when injected into the body, thereby enhancing its therapeutic window. The nanostructure taxis the CDN messengers directly to tumors and detaches the cargo only when reaching the target cells.

To evaluate the effectiveness of their approach, the team administered the CDN-nanoparticle (CDN-NP) compounds to mice with melanoma, colon cancer, and breast cancer tumors. They confirmed that their CDN-nanostructures were taken in by target immune cells in the tumor microenvironment and in secondary-lymphoid organs, providing mice long-term immunity against future tumors. When surviving mice were reintroduced with tumors 60 days after their initial treatment, they were able to reject the tumors on their own.

The team developed a set of design rules that must be considered when delivering immune therapy, including what the role of secondary lymphoid organs is in dictating therapeutic outcomes. They showed that the spleen plays a critical role in coaching the immune system to generate immune memory.

In addition to addressing fundamental questions about cancer and immunology, studies like this one show the potential of improving gene therapy delivery systems for treating diseases such as cancer.

In explaining the significance of the work, Artzi said, “Our research addresses the fundamental interplay between the immune system and cancer through the use of novel structure that has been designed to be both stable and potent. Moreover, we have demonstrated that targeting secondary lymphoid organs, such as the spleen, is crucial in generating long-lasting antitumor response which has important implications in how we think about immunotherapy delivery.”

More information:
Pere Dosta et al, Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles, Nature Nanotechnology (2023). DOI: 10.1038/s41565-023-01447-7

Provided by
Brigham and Women’s Hospital

Citation:
Researchers engineer nanostructures to enhance the immune system’s ability to combat cancer (2023, July 13)
retrieved 14 July 2023
from https://phys.org/news/2023-07-nanostructures-immune-ability-combat-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Previous Post

Taxpayers to pay over ksh700m for damage on nairobi expressway

Next Post

Azimio protests turn chaotic: Nairobi expressway barriers destroyed

Next Post

Azimio protests turn chaotic: Nairobi expressway barriers destroyed

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

The 31 Best Gadgets From CES 2025 You Can Buy Right Now

The 31 Best Gadgets From CES 2025 You Can Buy Right Now

5 months ago
New plans detail State Department layoffs and changes

New plans detail State Department layoffs and changes

2 weeks ago
Improved Security Lifts Nigeria’s Oil Output

Improved Security Lifts Nigeria’s Oil Output

10 months ago
The 5 African countries considered “role-models” in cyber security

The 5 African countries considered “role-models” in cyber security

9 months ago

POPULAR NEWS

  • Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    0 shares
    Share 0 Tweet 0
  • When Will SHIB Reach $1? Here’s What ChatGPT Says

    0 shares
    Share 0 Tweet 0
  • Matthew Slater, son of Jackson State great, happy to see HBCUs back at the forefront

    0 shares
    Share 0 Tweet 0
  • Dolly Varden Focuses on Adding Ounces the Remainder of 2023

    0 shares
    Share 0 Tweet 0
  • US Dollar Might Fall To 96-97 Range in March 2024

    0 shares
    Share 0 Tweet 0
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Politics
  • Markets
  • Crypto
  • Economics
    • Manufacturing
    • Real Estate
    • Infrastructure
  • Finance
  • Energy
  • Creator Economy
  • Wealth Management
  • Taxes
  • Telecoms
  • Military & Defense
  • Careers
  • Technology
  • Artificial Intelligence
  • Investigative journalism
  • Art & Culture
  • Documentaries
  • Quizzes
    • Enneagram quiz
  • Newsletters
    • LBNN Newsletter
    • Divergent Capitalist

© 2023 LBNN - All rights reserved.